IPO Details
Bidding Dates
29 Jan 25 - 31 Jan 25
Price Range ₹
382 - 402
Total Equity
₹ 3027.26Cr
Lot Size
35
Exchange Status
NSE,BSE
IPO Doc
Subscription Rate
Non-Institutional Investor
0.41×
Qualified Institutional Buyers
4.64×
Employees
0.27×
Retail Investors
0.41×
Total subscription Rate
1.55×
IPO Timeline
Offer start
29 Jan 2025
Offer end
31 Jan 2025
Allotment
03 Feb 2025
Refund initiation
04 Feb 2025
Demat transfer
04 Feb 2025
Listing
04 Feb 2025
Offer start
29 Jan 2025
Offer end
31 Jan 2025
Allotment
03 Feb 2025
Refund initiation
04 Feb 2025
Demat transfer
04 Feb 2025
Listing
04 Feb 2025
About Company
Incorporated in 2010, Dr. Agarwal's Health Care Limited provides a wide range of eye care services, including cataract and refractive surgeries, diagnostics, non-surgical treatments, and optical product sales. As of September 30, 2024, the company served 2.13 million patients and performed 220,523 surgeries, supported by 737 doctors across 193 facilities in 117 cities across 14 states and 4 union territories in India. The company’s services include cataract surgeries (e.g., robotic and glued intraocular lens treatments), refractive surgeries (e.g., LASIK, SMILE), and other eye-related procedures such as retinal treatments, corneal transplants, and glaucoma surgeries. Its network consists of 28 hubs and 165 spokes, offering advanced eye care through its extensive presence.
Year Founded
-
Promotor Details
Promoter Holdings Details
| Particular | Pre-IPO | Post-IPO |
|---|---|---|
| Percentage | 37.73 | 32.45 |
| Share Capital | 116359650 | 102504118 |
Offer to Public
7,53,04,970.00 Cr
Project Details
- Repayment/prepayment, in part or full, of certain of our borrowings - 1950cr
Objectives
- Our Company proposes to utilise the Net Proceeds from the Fresh Issue towards funding of the following objects:Repayment/prepayment, in part or full, of certain of our borrowings
- andGeneral corporate purposes and unidentified inorganic acquisition
Highlights
- Largest eye care services provider in India with a trusted and established brand.
- Comprehensive range of end-to-end eye care services.
- Scalable, asset-light hub-and-spoke operating model.
- Proven clinical excellence driven by a strong clinical board and innovative surgical practices.
- Doctor-led team of qualified professionals supported by experienced management, with a track record of organic growth and successful acquisitions.
Challenges
- Limited accessibility in remote areas, restricting service reach to certain populations.
- Intense competition from other well-established eye care providers in India.
- Dependence on skilled doctors for consistent service quality and performance.
- Significant expenses associated with advanced medical technologies and treatments.
- Potential impact of regulatory changes in the healthcare sector on operational flexibility and growth prospects.
Financials
| Years | Total Assets | Share Capital | Profit After Tax | Consolidated Net Profit | Adjusted EPS |
|---|---|---|---|---|---|
| 2022 | 10,119.85 | 68.60 | -5,838.09 | -5,547.83 | -2.6957 |
| 2024 | 27,161.30 | 93.60 | 1,032.30 | 940.97 | 3.9573 |
| 2020 | 73,967.25 | 686.00 | 1,032.30 | 940.97 | 3.9573 |
| 2023 | 17,697.17 | 79.26 | -5,838.09 | -5,547.83 | -2.6957 |
| 2021 | 77,376.92 | 686.00 | -1,964.97 | -2,053.10 | -0.9976 |
